Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements

NIST standard reference material (SRM) 2373 was developed to improve the measurements of the HER2 gene amplification in DNA samples. SRM 2373 consists of genomic DNA extracted from five breast cancer cell lines with different amounts of amplification of the HER2 gene. The five components are derived from the human cell lines SK-BR-3, MDA-MB-231, MDA-MB-361, MDA-MB-453, and BT-474. The certified values are the ratios of the HER2 gene copy numbers to the copy numbers of selected reference genes DCK, EIF5B, RPS27A, and PMM1. The ratios were measured using quantitative polymerase chain reaction and digital PCR, methods that gave similar ratios. The five components of SRM 2373 have certified HER2 amplification ratios that range from 1.3 to 17.7. The stability and homogeneity of the reference materials were shown by repeated measurements over a period of several years. SRM 2373 is a well characterized genomic DNA reference material that can be used to improve the confidence of the measurements of HER2 gene copy number.

[1]  Tania Nolan,et al.  The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. , 2013, Clinical chemistry.

[2]  Lili Wang,et al.  Breast cancer biomarker measurements and standards , 2013, Proteomics. Clinical applications.

[3]  Thomas D. Schmittgen,et al.  Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. , 2000, Analytical biochemistry.

[4]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jeff Mellen,et al.  High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.

[6]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[7]  A. Gown.  Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.

[8]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[9]  Z. Nemes,et al.  An Alternative and Reliable Real-time Quantitative PCR Method to Determine HER2/neu Amplification in Breast Cancer , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  Peter M Vallone,et al.  Production and certification of NIST Standard Reference Material 2372 Human DNA Quantitation Standard , 2009, Analytical and bioanalytical chemistry.

[11]  S N Austad.  Forensic DNA typing. , 1992, Science.

[12]  U. Lehmann,et al.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. , 2000, The American journal of pathology.

[13]  Russell G Foster,et al.  Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. , 2003, Nucleic acids research.

[14]  Alexandra S. Whale,et al.  Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation , 2012, Nucleic acids research.

[15]  C Caldas,et al.  Molecular cytogenetic analysis of breast cancer cell lines , 2000, British Journal of Cancer.

[16]  B. Ljung,et al.  HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  Benjamin J. Hindson,et al.  Evaluation of a Droplet Digital Polymerase Chain Reaction Format for DNA Copy Number Quantification , 2011, Analytical chemistry.

[18]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Melichar,et al.  Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR. , 2015, The Journal of molecular diagnostics : JMD.

[20]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[21]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[22]  F. B. Sørensen,et al.  Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. , 2004, The Journal of molecular diagnostics : JMD.

[23]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[24]  John M. Butler,et al.  Forensic DNA Typing: Biology, Technology, and Genetics of STR Markers , 2001 .

[25]  C. Larsson,et al.  Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping , 2000, Genes, chromosomes & cancer.

[26]  Jan Hellemans,et al.  Accurate and objective copy number profiling using real-time quantitative PCR. , 2010, Methods.

[27]  E. Frenkel,et al.  Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status , 2002, Modern Pathology.

[28]  P. Dundr,et al.  Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. , 2012, Molecular medicine reports.

[29]  Stephen A. Wise,et al.  Standard Reference Materials: Definitions of terms and modes used at NIST for value-assignment of reference materials for chemical measurements , 2000 .

[30]  Malorye Allison.  The HER2 testing conundrum , 2010, Nature Biotechnology.

[31]  N. Turner,et al.  Determination of HER2 Amplification Status on Tumour DNA by Digital PCR , 2013, PloS one.

[32]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[33]  S. Devries,et al.  Genetic alterations in ERBB2-amplified breast carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[35]  S. Chariyalertsak,et al.  Her-2/neu amplification determined by real-time quantitative PCR and its association with clinical outcome of breast cancer in Thailand. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[36]  Benjamin J Hindson,et al.  Droplet digital PCR measurement of HER2 copy number alteration in formalin-fixed paraffin-embedded breast carcinoma tissue. , 2013, Clinical chemistry.